REFERENCES
1. Tunstall O, Bhatnagar N, James B, et al. Guidelines for the
investigation and management of Transient Leukaemia of Down Syndrome.Br J Haematol. 2018;182(2):200-211.
2. Johann Hitzler M, FRCP(C), FAAPMoira Garraus, MD. Transient
Myeloproliferative Disorder of Down Syndrome.
https://www.uptodate.com/contents/transient-myeloproliferative-disorder-of-down-syndrome.
Published March 2020. Updated March 2020. Accessed January 25 2021,
2021.
3. Bhatnagar N, Nizery L, Tunstall O, Vyas P, Roberts I. Transient
Abnormal Myelopoiesis and AML in Down Syndrome: an Update. Curr
Hematol Malig Rep. 2016;11(5):333-341.
4. Brink DS. Transient leukemia (transient myeloproliferative disorder,
transient abnormal myelopoiesis) of Down syndrome. Adv Anat
Pathol. 2006;13(5):256-262.
5. Watanabe K. Recent advances in the understanding of transient
abnormal myelopoiesis in Down syndrome. Pediatr Int.2019;61(3):222-229.
6. Kikuchi A, Tamura N, Ishii K, et al. Four cases of fetal hypoechoic
hepatomegaly associated with Trisomy 21 and transient abnormal
myelopoiesis. Prenat Diagn. 2007;27(7):665-669.
7. Rizzo A, Perotti G, Fiandrino G, Spinillo A, Stronati M, Iasci A.
Prenatal diagnosis of transient abnormal myelopoiesis in three fetuses
with Down syndrome: heterogeneous ultrasonographic findings and
outcomes. Ultrasound Obstet Gynecol. 2018;51(3):412-413.
8. Shimizu R, Engel JD, Yamamoto M. GATA1-related leukaemias. Nat
Rev Cancer. 2008;8(4):279-287.
9. Gruber TA, Downing JR. The biology of pediatric acute
megakaryoblastic leukemia. Blood. 2015;126(8):943-949.
10. Roy A, Roberts I, Norton A, Vyas P. Acute megakaryoblastic leukaemia
(AMKL) and transient myeloproliferative disorder (TMD) in Down syndrome:
a multi-step model of myeloid leukaemogenesis. Br J Haematol.2009;147(1):3-12.
11. Gamis AS, Alonzo TA, Gerbing RB, et al. Natural history of transient
myeloproliferative disorder clinically diagnosed in Down syndrome
neonates: a report from the Children’s Oncology Group Study A2971.Blood. 2011;118(26):6752-6759; quiz 6996.
12. Flasinski M, Scheibke K, Zimmermann M, et al. Low-dose cytarabine to
prevent myeloid leukemia in children with Down syndrome: TMD Prevention
2007 study. Blood Adv. 2018;2(13):1532-1540.
13. Khan I, Malinge S, Crispino J. Myeloid leukemia in Down syndrome.Crit Rev Oncog. 2011;16(1-2):25-36.
14. Massey GV, Zipursky A, Chang MN, et al. A prospective study of the
natural history of transient leukemia (TL) in neonates with Down
syndrome (DS): Children’s Oncology Group (COG) study POG-9481.Blood. 2006;107(12):4606-4613.
15. Bull MJ, Committee on G. Health supervision for children with Down
syndrome. Pediatrics. 2011;128(2):393-406.